These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 28708284)

  • 1. CD20-Specific Immunoligands Engaging NKG2D Enhance γδ T Cell-Mediated Lysis of Lymphoma Cells.
    Peipp M; Wesch D; Oberg HH; Lutz S; Muskulus A; van de Winkel JGJ; Parren PWHI; Burger R; Humpe A; Kabelitz D; Gramatzki M; Kellner C
    Scand J Immunol; 2017 Oct; 86(4):196-206. PubMed ID: 28708284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30.
    Kellner C; Günther A; Humpe A; Repp R; Klausz K; Derer S; Valerius T; Ritgen M; Brüggemann M; van de Winkel JG; Parren PW; Kneba M; Gramatzki M; Peipp M
    Oncoimmunology; 2016; 5(1):e1058459. PubMed ID: 26942070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity.
    Kellner C; Maurer T; Hallack D; Repp R; van de Winkel JG; Parren PW; Valerius T; Humpe A; Gramatzki M; Peipp M
    J Immunol; 2012 Nov; 189(10):5037-46. PubMed ID: 23066150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition.
    Wrobel P; Shojaei H; Schittek B; Gieseler F; Wollenberg B; Kalthoff H; Kabelitz D; Wesch D
    Scand J Immunol; 2007; 66(2-3):320-8. PubMed ID: 17635809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NK cell-mediated anti-leukemia cytotoxicity is enhanced using a NKG2D ligand MICA and anti-CD20 scfv chimeric protein.
    Zou Y; Luo W; Guo J; Luo Q; Deng M; Lu Z; Fang Y; Zhang CC
    Eur J Immunol; 2018 Oct; 48(10):1750-1763. PubMed ID: 30063799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicity.
    Kellner C; Hallack D; Glorius P; Staudinger M; Mohseni Nodehi S; de Weers M; van de Winkel JG; Parren PW; Stauch M; Valerius T; Repp R; Humpe A; Gramatzki M; Peipp M
    Leukemia; 2012 Apr; 26(4):830-4. PubMed ID: 22005785
    [No Abstract]   [Full Text] [Related]  

  • 7. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
    Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A
    Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib enhances cytotoxicity of ex vivo-expanded gamma delta T cells against acute myeloid leukemia and T-cell acute lymphoblastic leukemia.
    Story JY; Zoine JT; Burnham RE; Hamilton JAG; Spencer HT; Doering CB; Raikar SS
    Cytotherapy; 2021 Jan; 23(1):12-24. PubMed ID: 33168453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma.
    Rothe A; Jachimowicz RD; Borchmann S; Madlener M; Keßler J; Reiners KS; Sauer M; Hansen HP; Ullrich RT; Chatterjee S; Borchmann P; Yazaki P; Koslowsky TC; Engert A; Heukamp LC; Hallek M; von Strandmann EP
    Int J Cancer; 2014 Jun; 134(12):2829-40. PubMed ID: 24242212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
    Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
    FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct pattern of human Vdelta1 gammadelta T cells recognizing MICA.
    Li J; Cui L; He W
    Cell Mol Immunol; 2005 Aug; 2(4):253-8. PubMed ID: 16274622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of in vitro and in vivo NK cell cytotoxicity using high-avidity immunoligands targeting prostate-specific membrane antigen in prostate carcinoma.
    Jachimowicz RD; Fracasso G; Yazaki PJ; Power BE; Borchmann P; Engert A; Hansen HP; Reiners KS; Marie M; von Strandmann EP; Rothe A
    Mol Cancer Ther; 2011 Jun; 10(6):1036-45. PubMed ID: 21525185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of V gamma 9V delta 2 T cells by NKG2D.
    Rincon-Orozco B; Kunzmann V; Wrobel P; Kabelitz D; Steinle A; Herrmann T
    J Immunol; 2005 Aug; 175(4):2144-51. PubMed ID: 16081780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells.
    Zhang T; Sentman CL
    Cancer Res; 2011 Mar; 71(6):2066-76. PubMed ID: 21282338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CBP/p300 acetyltransferases regulate the expression of NKG2D ligands on tumor cells.
    Sauer M; Schuldner M; Hoffmann N; Cetintas A; Reiners KS; Shatnyeva O; Hallek M; Hansen HP; Gasser S; von Strandmann EP
    Oncogene; 2017 Feb; 36(7):933-941. PubMed ID: 27477692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The histone deacetylase inhibitor SAHA simultaneously reactivates HIV-1 from latency and up-regulates NKG2D ligands sensitizing for natural killer cell cytotoxicity.
    Desimio MG; Giuliani E; Doria M
    Virology; 2017 Oct; 510():9-21. PubMed ID: 28689087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity.
    Peipp M; Derer S; Lohse S; Staudinger M; Klausz K; Valerius T; Gramatzki M; Kellner C
    Oncotarget; 2015 Oct; 6(31):32075-88. PubMed ID: 26392331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decitabine Enhances Vγ9Vδ2 T Cell-Mediated Cytotoxic Effects on Osteosarcoma Cells
    Wang Z; Wang Z; Li S; Li B; Sun L; Li H; Lin P; Wang S; Teng W; Zhou X; Ye Z
    Front Immunol; 2018; 9():1239. PubMed ID: 29910819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NKG2D ligand expression in Crohn's disease and NKG2D-dependent stimulation of CD8
    Vadstrup K; Galsgaard ED; Jensen H; Lanier LL; Ryan JC; Chen SY; Nolan GP; Vester-Andersen MK; Pedersen JS; Gerwien J; Jensen T; Bendtsen F
    Exp Mol Pathol; 2017 Aug; 103(1):56-70. PubMed ID: 28684217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CMV-independent lysis of glioblastoma by ex vivo expanded/activated Vδ1+ γδ T cells.
    Knight A; Arnouk H; Britt W; Gillespie GY; Cloud GA; Harkins L; Su Y; Lowdell MW; Lamb LS
    PLoS One; 2013; 8(8):e68729. PubMed ID: 23950874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.